Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Effective treatment for pancreatic cancer remains challenging, particularly the treatment of pancreatic ductal adenocarcinoma (PDAC), which makes up more than 95% of all pancreatic cancers. Late diagnosis and failure of chemotherapy and radiotherapy are all too common, and many patients die soon after diagnosis. Here, we make the case for the increased use of molecular imaging in PDAC preclinical research and in patient management.

Original publication

DOI

10.1007/s00259-018-4146-5

Type

Journal article

Journal

Eur J Nucl Med Mol Imaging

Publication Date

12/2018

Volume

45

Pages

2442 - 2455

Keywords

Molecular imaging, PET, Pancreatic ductal adenocarcinoma, Preclinical developments, SPECT, Animals, Humans, Molecular Imaging, Pancreas, Exocrine, Pancreatic Neoplasms, Translational Medical Research